Table 1.
Histopathological features of tumors
| ER+ | ER-PR-HER2- | ER-PR-HER2+ | ER-PR+ | P-value | |
|---|---|---|---|---|---|
| n=2012 (75.4%) | n=311 (11.7%) | n=220 (8.2%) | n=126 (4.7%) | ||
| Age | |||||
| <60 | 1266 (75%) | 204 (12.1%) | 129 (7.6%) | 88 (5.2%) | 0.000 |
| ≥60 | 742 (75.8%) | 107 (11%) | 91 (9.3%) | 38 (3.9%) | |
| Menopause | |||||
| Pre | 1076 (53.5%) | 171 (55%) | 116 (52.7%) | 75 (59.5%) | 0.001 |
| post | 915 (45.5%) | 140 (45%) | 104 (47.3%) | 51 (40.5%) | |
| Grade | |||||
| I/II | 1203 (59.8%) | 66 (21.2%) | 70 (31.8%) | 35 (27.8%) | 0.000 |
| III | 588 (29.2%) | 217 (69.8%) | 132 (60%) | 78 (61.9%) | |
| Tumor size | |||||
| ≤5 cm | 1579 (78.5%) | 245 (78.8%) | 143 (65%) | 91 (72.2%) | 0.000 |
| >5 cm | 358 (17.9%) | 56 (18%) | 67 (30.4%) | 28 (22.2%) | |
| Node | |||||
| N0 | 1472 (73.2%) | 226 (72.7%) | 129 (58.6%) | 87 (69%) | 0.000 |
| N+ | 540 (26.8%) | 85 (27.3%) | 91 (41.4%) | 39 (31%) | |
| Treatment | |||||
| No | 147 (7.3%) | 11 (3.5%) | 13 (5.9%) | 7 (5.6%) | |
| Chemotherapy | 1385 (68.8%) | 293 (94.3%) | 204 (92.7%) | 112 (88.8%) | |
| Only hormone | 441 (21.9%) | 0 | 0 | 7 (5.6%) | |
| Unknown | 39 (1.9%) | 7 (2.2%) | 3 (1.4%) | 0 | |
| RT+ | 1408 (70%) | 221 (71.1%) | 165 (75%) | 95 (75.4%) |